Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03910387 · ClinicalTrials.gov registry record · Phase 2
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03910387 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 23 participants.
The verdict
NCT03910387, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may help patients tolerate chemotherapy better and improve longevity.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Telotristat Ethyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-04-17 |
| Est. Completion | 2022-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03910387
The ClinicalTrials.gov registry entry for NCT03910387 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03910387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03910387 about?
NCT03910387 is a clinical study titled "Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer". This phase II trial studies how well telotristat ethyl works in promoting weight stability in patients with pancreatic adenocarcinoma that has come back and spread to other places in the body. Telotristat ethyl may decrease bowel movements which may make patients gain weight. Stabilizing weight may ...
What is the current status of trial NCT03910387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-04-17. Estimated completion is 2022-06-29.
What interventions are being tested in trial NCT03910387?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Telotristat Ethyl (DRUG).
Who is sponsoring clinical trial NCT03910387?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.